Skip to main content

RETRACTION article

Front. Med., 10 June 2022
Sec. Infectious Diseases – Surveillance, Prevention and Treatment
Volume 9 - 2022 | https://doi.org/10.3389/fmed.2022.964099

Retraction: Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial

A Retraction of the Original Research Article
Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial

by McCoy, J., Goren, A., Cadegiani, F. A., Vaño-Galván, S., Kovacevic, M., Situm, M., Shapiro, J., Sinclair, R., Tosti, A., Stanimirovic, A., Fonseca, D., Dorner, E., Onety, D. C., Zimerman, R. A., and Wambier, C. G. (2021). Front. Med. 8:668698. doi: 10.3389/fmed.2021.668698

The journal and Chief Editors have retracted the 19 July 2021 article cited above.

Shortly after publication, our office received letters of complaint questioning the integrity of the article, following which an Expression of Concern was published and a thorough investigation was conducted, in accordance with our policies and COPE guidelines.

The investigation found that the claims made in the conclusions were not adequately supported by the methodology of the study. In particular, as confirmed by an external expert, the process of allocation to treatment and control was not sufficiently random.

This retraction was approved by the Chief Editors of Frontiers in Medicine and the Chief Executive Editor of Frontiers. The authors disagree with this retraction.

Citation: Frontiers Editorial Office (2022) Retraction: Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial. Front. Med. 9:964099. doi: 10.3389/fmed.2022.964099

Received: 08 June 2022; Accepted: 08 June 2022;
Published: 10 June 2022.

Approved by:

Marc Jean Struelens, Université libre de Bruxelles, Belgium

Copyright © 2022 Frontiers Editorial Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Frontiers Editorial Office, editorial.office@frontiersin.org

Download